Page last updated: 2024-11-05

1,2-epoxy-3-(p-nitrophenoxy)propane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2-epoxy-3-(p-nitrophenoxy)propane: a protease inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,2-epoxy-3-(4-nitrophenoxy)propane : An epoxide that is oxirane substituted by a (4-nitrophenoxy)methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID21327
CHEMBL ID33775
CHEBI ID508
SCHEMBL ID517975
MeSH IDM0050895

Synonyms (63)

Synonym
nsc-1733
p-nitrophenyl glycidyl ether
p-nitrophenol glycidyl ether
propane,2-epoxy-3-(p-nitrophenoxy)-
glycidyl 4-nitrophenyl ether
1-(p-nitrophenoxy)-2,3-epoxypropane
glycidylnitrophenyl ether
oxirane, [(4-nitrophenoxy)methyl]-
nsc1733
2,3-epoxy-1-(p-nitrophenoxy)propane
1,2-epoxy-3-(4-nitrophenoxy)propane
nitrophenyl glycidyl ether
1,2-epoxy-3-(4'-nitrophenoxy)propane
CHEBI:508 ,
ccris 6429
nitrophenyl glycidyl ether, p-
einecs 226-057-3
propane, 1,2-epoxy-3-(p-nitrophenoxy)-
nsc 1733
p-nitrophenylglycidyl ether
glycidyl p-nitrophenyl ether
1,2-epoxy-3(p-nitrophenoxy)-propane
((4-nitrophenoxy)methyl)oxirane
((p-nitrophenoxy)methyl)oxirane
oxirane, ((4-nitrophenoxy)methyl)-
1,2-epoxy-3-(p-nitrophenoxy)propane
5255-75-4
C04274
epnp
2-[(4-nitrophenoxy)methyl]oxirane
CHEMBL33775 ,
AKOS000149480
bdbm50284985
1,2-epoxy-3-(4''-nitrophenoxy)propane
2-((4-nitrophenoxy)methyl)oxirane
A7692
unii-96071991u0
96071991u0 ,
oxirane, 2-((4-nitrophenoxy)methyl)-
FT-0610824
SCHEMBL517975
2-[(4-nitrophenoxy)methyl]-oxirane
2-(4-nitro-phenoxymethyl)-oxirane
1,2-epoxy-3-(p-nitrophenoxy)-propane
3-(4-nitrophenyloxy)-1,2-epoxypropane
4-(2,3-epoxypropoxy) nitrobenzene
2-(4-nitrophenoxymethyl)-oxirane
1-(4-nitrophenoxy)-2,3-epoxypropane
4-(2,3-epoxypropoxy)nitrobenzene
2-[(4-nitrophenoxy)methyl]oxirane #
oxirane, 2-[(4-nitrophenoxy)methyl]-
(2r)-2-[(4-nitrophenoxy)methyl]-oxirane
J-500938
AKOS016843596
4-nitrophenyl glycidyl ether
mfcd00041845
DTXSID60863512
STL582583
CS-0205886
Q27105305
AMY24751
PS-10361
PD195113

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Preexposure of daphnids to CDNB or PCP increased the organisms' tolerance to the toxic effects of PCP, but not CDNB."( Modulation of substrate-specific glutathione S-transferase activity in Daphnia magna with concomitant effects on toxicity tolerance.
Cochrane, BJ; LeBlanc, GA, 1985
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Rabbits and rats dosed with 1,2-epoxy-3-phenoxypropane excrete 2-hydroxy-3-phenoxypropionic acid and N-acetyl-S-(2-hydroxy-3-phenoxypropyl)-L-cysteine."( Metabolites of 1,2-epoxy-3-phenoxy- and 1,2-epoxy-3-(p-nitrophenoxy)propane.
James, SP; Pheasant, AE; Solheim, E, 1978
)
0.53
" Here, we examined the expression and activity of GSTZ1 in cytosol and mitochondria of liver, kidney, heart, and brain 24 hours after completion of 8-day oral dosing of 100 mg/kg per day sodium DCA to juvenile and adult Sprague Dawley rats."( Effects of Multiple Doses of Dichloroacetate on GSTZ1 Expression and Activity in Liver and Extrahepatic Tissues of Young and Adult Rats.
Horne, LP; James, MO; Rowland-Faux, L; Smeltz, MG; Squirewell, EJ; Stacpoole, PW, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (27.91)18.7374
1990's16 (37.21)18.2507
2000's11 (25.58)29.6817
2010's3 (6.98)24.3611
2020's1 (2.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.59 (24.57)
Research Supply Index3.78 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.33%)4.05%
Observational0 (0.00%)0.25%
Other42 (97.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]